by Jen Hodson | Oct 29, 2018 | Press Releases
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY, CA – (October 29, 2018) — Significant developments in cancer research were presented by NantHealth...
by Jen Hodson | Aug 27, 2018 | Press Releases
Clinical Trial Tests Personalized Treatments in Push to Improve Pediatric Cancer Survival UCSF Benioff Children’s Hospitals are harnessing next-generation genomic technology to develop individualized drug cocktails in a new trial for children with a type of malignant...
by Jen Hodson | Aug 27, 2018 | Press Releases
Peer-reviewed research utilizing NantOmics technology gives scientists fresh insights into driving mechanisms behind a form of rare skin cancer. August 27,2018 – CULVER CITY, Calif — New, peer-reviewed research utilizing NantOmics technology, which powers...
by Jen Hodson | Jun 12, 2018 | Press Releases
7:02 pm MST | Jun 8, 2018 | BioCentury | Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior Writer Download Article...
by Jen Hodson | Jun 4, 2018 | Press Releases
Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...
